安全评估、风险诊断、隐患排查……不同于传统的企业内部安全管理模式，如今，越来越多的生产 经营单位开始借助专业的社会化服务机构来提升安全生产水平，许多新的服务模式也在不断涌现。 规范的市场需要有效的监管保障，如何强监管？《办法》从政府监管、行业自律、社会监督等方面 作出规定。 在政府监管层面，《办法》要求负有安全生产监督管理职责的部门通过日常抽查、专项检查、举报 核查等多种方式开展监督检查。特别值得关注的是，在生产安全事故调查中，相关服务机构及其从业人 员必须配合接受延伸调查，监管部门将依法提出相应的处理意见，实现了事前规范与事后追责的有机统 一。 近日，山东公布《山东省安全生产社会化服务机构管理办法》（以下简称《办法》），《办法》自 2025年10月1日起施行，围绕适用范围与从业要求、责任落实与禁止行为、监管体制与处罚措施等方 面，提出23条具体规定。 在行业自律方面，《办法》鼓励服务机构成立行业协会，通过加强职业道德教育和专业技能培训， 完善服务标准体系，推动行业自我管理、自我约束、自我发展。（记者 杨成） 在合作关系中，《办法》要求生产经营单位对服务过程进行有效监督，对机构提出的事故预防措 施、隐患整改意 ...

Core Viewpoint - The rapid integration of internet healthcare and artificial intelligence (AI) is driving significant interest and investment in AI healthcare stocks, particularly in the Hong Kong market, where related stocks have seen substantial price increases [1][2][3]. Group 1: Market Performance - The Hong Kong healthcare index has been rising, benefiting AI healthcare stocks, with notable price increases such as Health Road's stock rising by 5.57% and a total increase of 49.13% over three trading days since June 2 [1]. - Other companies like Meili Tianyuan Medical and CloudTop New Drug have also experienced significant stock price increases, with Meili Tianyuan's stock rising by 34.25% and CloudTop New Drug by 5.16% [1]. - The performance of AI healthcare stocks has positively impacted public fund products, attracting substantial institutional investment despite high valuations [1][2]. Group 2: Fund Strategies - Many pharmaceutical funds are shifting their top holdings from innovative drug stocks to AI healthcare companies, with examples including Silver Hua Fund's top three holdings now being AI healthcare firms [2]. - Even bond-focused public funds are showing interest in high-volatility AI healthcare stocks, indicating a broadening appeal across different fund types [2]. - The Hang Seng Medical ETF has seen a 34.69% increase since April 9, reflecting the growing interest in AI healthcare investments [2]. Group 3: Investment Opportunities - Investment opportunities in the AI healthcare sector are concentrated in three main areas: AI drug development, AI medical applications, and data production and application [3][4]. - AI technology is expected to enhance the efficiency of new drug development, with several AI-assisted drugs entering clinical validation stages [3]. - The integration of AI in traditional medical practices is anticipated to improve diagnostic efficiency and capabilities, while also reducing costs in drug development [4]. Group 4: Industry Trends - The AI healthcare sector is experiencing a clear trend towards commercialization, with significant orders in health management, clinical decision support, imaging diagnostics, and drug development [5]. - The Chinese government is promoting AI applications in the pharmaceutical industry, supporting the establishment of innovative platforms and pilot projects across the entire pharmaceutical value chain [4][5]. - Companies are actively recruiting talent with expertise in both medicine and AI to enhance their capabilities in clinical decision-making and drug development [5].